Tong Ming, Xu Zhong, Ai Jun-kui, Yuan Yi-ming, Yin Yi, Wang Jun-qi, Li Hong-wei, Liu Jian-he, Xin Dian-qi, Zhou Li-qun, Li Ming, Na Yan-qun
Institute of Urology, First Hospital, Peking University, Beijing 100034, China.
Zhonghua Wai Ke Za Zhi. 2004 Dec 22;42(24):1493-6.
The correlation were studied between testosterone 5-alpha-reductase II (SRD5A2) gene polymorphisms and prognosis factors.
V89L and A49T variants was identified with Mwo1 and Rsa1. The differences of V89L and A49T between cancer of prostate (CaP) and benign prostatic hyperplasia (BPH) were studied. In addition, we also researched the association of polymorphisms with age of onset, free prostate specific antigen (FPSA), total PSA (TPSA), FPSA/TPSA (F/T), Gleason score, and T stage in cancer group.
We found no differences of V89L and A49T polymorphisms between CaP and BPH. In CaP group the A49T variant was associated with lower age of onset (P = 0.03) and higher Gleason score (P = 0.015). There were no differences between VV and VL+LL polymorphisms with any of the characteristics studied. When the characteristics above were regarded as two-level discrete variable, there were no differences by A49T and V89Lvariants.
In CaP group, the AT+TT genotype was perhaps associated with poor prognosis. VL+LL genotype has no relation with prognosis.
研究睾酮5α-还原酶II（SRD5A2）基因多态性与预后因素之间的相关性。
采用Mwo1和Rsa1鉴定V89L和A49T变异。研究前列腺癌（CaP）和良性前列腺增生（BPH）之间V89L和A49T的差异。此外，我们还研究了多态性与癌症组发病年龄、游离前列腺特异性抗原（FPSA）、总前列腺特异性抗原（TPSA）、FPSA/TPSA（F/T）、Gleason评分和T分期的相关性。
我们发现CaP和BPH之间V89L和A49T多态性没有差异。在CaP组中，A49T变异与较低的发病年龄（P = 0.03）和较高的Gleason评分（P = 0.015）相关。VV与VL + LL多态性在任何研究特征之间均无差异。当将上述特征视为二级离散变量时，A49T和V89L变异无差异。
在CaP组中，AT + TT基因型可能与预后不良相关。VL + LL基因型与预后无关。
